Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2009-01-01
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Doxycycline and Ceftriaxone in Suspected Early Lyme Neuroborreliosis
NCT00942006
Clinical Manifestations and Long-Term Outcome in Early Lyme Neuroborreliosis
NCT04653558
Study of Lyme Neuroborreliosis
NCT01635530
Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis
NCT00138801
Erythema Migrans in Elderly
NCT03371563
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early Lyme neuroborreliosis patients
ceftriaxone
ceftriaxone 2 g od i.v. for 14 days
control subjects
Control subjects without a history of Lyme borreliosis.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ceftriaxone
ceftriaxone 2 g od i.v. for 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* lactation
* history of adverse reaction to a beta-lactam antibiotic
15 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Franc Strle
M.D., PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Franc Strle, MD
Role: STUDY_CHAIR
UMC Ljubljana
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UMC Ljubljana, Department of Infectious Diseases
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LNB-0509
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.